Publications

Species distribution and antifungal susceptibility patterns for Candida isolates from the SENTRY Antimicrobial Surveillance Program (Europe), Lead author: Prodhom G, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Prevalence and resistance rates of Enterobacter spp. in nosocomial infections, Euro-SENTRY Antimicrobial Surveillance program, 1997-2001, Lead author: Rodriguez-Villalobos H, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Evolution of an integron carrying blaVIM-2 in Central Europe: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Toleman MA, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Epidemiology of the new metallo-beta-lactamase gene, blaSPM, in South America: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Toleman MA, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Analysis of the blaVIM gene context from Italy reveals novel resistant cassettes: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Toleman MA, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens from intensive care units in Latin American medical centers: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Sader HS, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. by Diekema DJ, Andrews JI, Huynh H, Rhomberg PR, Doktor SR, Beyer J, Shortridge VD, Flamm RK, Jones RN and Pfaller MA published in J. Clin. Microbiol. 2003; 41 (6): 2659-2661

Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae. by Anderegg TR, Biedenbach DJ, Jones RN and The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 1996; 46: 147-150

Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. by Anderegg TR, Biedenbach DJ, Jones RN and The Quality Control Working Group published in J. Clin. Microbiol. 2003; 41 (6): 2795-2796

Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. by Mutnick AH, Enne V and Jones RN published in Ann. Pharmacol. 2003; 37 (6): 769-774

Initial disk diffusion quality control guidelines for tylosin tested against Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619. by Anderegg TR, Jones RN and The Quality Control Working Group published in Int. J. Antimicrob. Agents 2003; 21 (6): 594-596

Results of the survey of the quality assurance for commercially prepared microbiology media. Update from the College of American Pathologists Microbiology Surveys Program (2001). by Jones RN, Krisher K, Bird DS and CAP Microbiology Resource Committee published in Arch. Pathol. Lab. Med. 2003; 127 (6): 661-665

Initial description of the L22 mutation responsible for quinupristin/dalfopristin resistance in Streptococcus pneumoniae: Case reports from the SENTRY Antimicrobial Surveillance Program. Abstr. P1548. by Jones RN, Farrell D, Morrissey I on Behalf of the SENTRY Participants Group published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 377

Comparative activity of garenoxacin against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae isolates: Report from the SENTRY Antimicrobial Surveillance Program (Europe, 1999 – 2001) by Canton R, Loza E, Morosini MI, Baquero F, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 347

Contemporary activity of grepafloxacin: Re-evaluation of antimicrobial features of a potent fluoroquinolone. Abstr. P1429. by Jones RN, Gordon KA, Rhomberg R, Fritsche TR, Sader HS published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1):346

Characterization of antimicrobial susceptibility patterns among community-acquired isolates of beta-haemolytic streptococci in Latin America: Results from the SENTRY Antimicrobial Surveillance Program (2001). Abstr. P1306 by Gales AC, Sader HS, Castanheira M, Jones RN on Behalf of the SENTRY Group – Latin America published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1):315

Epidemiology and frequency of antimicrobial resistances among pathogens causing surgical site infections: Report from the SENTRY Antimicrobial Surveillance Program in the United States, Canada, and Europe. by Mathai D, Biedenbach DJ, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1):287-288

Comparative antimicrobial potency and spectrum of activity for meropenem and nine comparator agents: Report from the United States MYSTIC Program Surveillance Study in 2002. Abstr P1040. by Rhomberg PR, Mutnick AH, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 243

Antimicrobial usage and resistance trend comparisons from the MYSTIC Program in North America (1999 – 2001). Abstr. P1039. by Mutnick AH, Rhomberg PR, Jones RN published in Clin. Microbiol. Infect. 2003; 9(Suppl 1):243

Relationships between susceptibility of Pseudomonas aeruginosa and hospital- and patient-specific variables. Report from the Antimicrobial Resistant Rate Epidemiology Study Team (ARREST Program). Abstr. P1037. by Bhavnani SM, Hammel JP, Ambrose PG, Forrest A, Rubino CM and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): S242-S243

Relationships between susceptibility of Streptococcus pneumoniae and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program). Abstr. P1036. by Bhavnani SM, Hammel JP, Forrest A, Ambrose PG and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 242

Relationships between susceptibility of Enterobacter spp. and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program). by Bhavnani SM, Hammel JP, Forrest A, Ambrose PG and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 241-242

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens from intensive care units in Latin American medical centers: Report from the SENTRY Antimicrobial Surveillance Program by Sader HS, Gales AC, Mendes RE and Jones RN on Behalf of the SENTRY Group – Latin America published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 226

Epidemiology of the new metallo-beta-lactamase gene blaSPM, in South America: Report from the SENTRY Antimicrobial Surveillance Program. Abstr. P718. by Toleman M, Bennett D, Walsh T, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1):156-157

Evolution of an integron carrying blaVIM-2 in Central Europe: Report from the SENTRY Antimicrobial Surveillance Program. Abstr. P717. by Toleman MA, Hryniewicz W, Bennett P, Jones RN and Walsh TR published in Clin Microbiol Infect 2003; 9 (Suppl 1): 156

Prevalence and resistance rates of Enterobacter spp. in nosocomial infections, Euro-SENTRY Antimicrobial Surveillance Program, 1997 – 2001. Abstr. P714. by Rodriguez-Villalobos H, Struelens MJ and Jones RN on Behalf of the Euro-SENTRY Participants published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 155

Species distribution and antifungal susceptibility patterns for Candida isolates from the SENTRY Antimicrobial Surveillance Program (Europe). Abstr. P713. by Prod’hom G, Bille J, Jones RN and The SENTRY Participants Group in Europe published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 155

Cloning of a hybrid metallo-beta-lactamase gene conferring a novel IMP variant blaIMP-13 in Pseudomonas aeruginosa in Italy: Report from the SENTRY Antimicrobial Surveillance Program by Toleman MA, Jones RN, Walsh TR published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 119

Analysis of the blaVIM gene context from Italy reveals novel resistant cassettes: Report from the SENTRY Antimicrobial Surveillance Program. by Toleman MA, Bennett D, Jones RN, Walsh TR published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 119

Over-expression of a novel RamA from Enterobacter cloacae confers carbapenem resistance in E. coli: Report from the SENTRY Antimicrobial Surveillance Program by Toleman MA, Jones RN and Walsh TR published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 53-54

Pharmacokinetics-pharmacodynamics of cefepime and piperacillin/tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum ß-lactamases: Report from the ARREST Program. by Ambrose PG, Bhavnani SM and Jones RN published in Antimicrob. Agents Chemother. 2003; 47 (5): 1643-1646

Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000 – 2001): Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Biedenbach DJ and Beach ML published in Diagn. Microbiol. Infect. Dis. 2003; 46 (1): 77-80

Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: Prevalence results from the SENTRY Antimicrobial Surveillance Program. by Biedenbach DJ, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (1): 55-61

Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997 – 2000). by Mutnick AH, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (1): 63-68

Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: Comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). by Gordon KA, Jones RN and The SENTRY Participant Groups (Europe, Latin America, North America) published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 295-301

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). by Rennie RP, Jones RN, Mutnick AH and The SENTRY Program Study Group (North America) published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 287-293

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: Results of the SENTRY Antimicrobial Surveillance Study (2000). by Hoban DJ, Biedenbach DJ, Mutnick AH and Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 279-285

Comparative activity of garenoxacin (BMS284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). by Jones RN, Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 273-278

Confirmation of extended-spectrum ß-lactamase-producing Serratia marcescens: Preliminary report from Taiwan. by Yu WL, Wu LT, Pfaller MA, Winokur PL, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 221-224

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN published in Antimicrob. Agents Chemother. 2003; 47 (3): 1068-1071

Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: A five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). by Jones RN published in Semin. Resp. Crit. Care Med. 2003; 24 (1): 121-134

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. by Bell JM, Turnidge JD, Ballow CH, Jones RN and ZAPS Regional Participants published in J. Antimicrob. Chemother. 2003; 51 (2): 339-345

Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa. by Murphy TA, Simm AM, Toleman MA, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2003; 47 (2): 582-587

Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. by Jones RN, Rhomberg PR published in J. Antimicrob. Chemother. 2003; 51 (1): 157-161

Emergence of an IMP-Like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. by Gales AC, Tognim MCB, Reis AO, Jones RN, Sader HS published in Diagn. Microbiol. Infect. Dis. 2003; 45 (1): 77-79

Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone. by Anderegg TR, Jones RN, The Quality Control Study Group published in Diagn. Microbiol. Infect. Dis. 2003; 45 (1): 73-76

Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans. by Yamazumi T, Pfaller MA, Messer SA, Houston AK, Boyken L, Hollis RJ, Furuta I, Jones RN published in J. Clin. Microbiol. 2003; 41 (1): 267-272

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN and International Fungal Surveillance Participant Group published in J. Clin. Microbiol. 2003; 41 (1): 78-83

Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. by Jones RN, Rubino CM, Bhavnani SJ and Ambrose PG published in Antimicrob. Agents Chemother. 2003; 47 (1): 292-296

CANCER Resistance Surveillance Program: initial results from hematology-oncology centers in North America. by Mutnick AH, Kirby JT, Jones RN and CANCER Study Group published in Ann. Pharmacol. 2003; 37 (1): 47-56